Jaguar Health 获得使用植物性药物 crofelemer 治疗短肠综合征的专利。 Jaguar Health receives patent for treating short bowel syndrome with plant-based drug crofelemer.

Jaguar Health 获得约旦工业产权保护局的专利，用于使用其植物性药物 crofelemer 治疗短肠综合征 （SBS）。 Jaguar Health receives a patent from Jordan's Industrial Property Protection Directorate for treating short bowel syndrome (SBS) with its plant-based drug, crofelemer. 专利加强了Jaguar公司对其罕见疾病核心目标指标SBS的知识产权保护。 The patent strengthens Jaguar's intellectual property protection for its core rare disease target indication, SBS. 美国,欧盟和中东/北非地区正在进行SBS和微型病毒包容性疾病中crofelemer的概念验证研究,预计结果将在2024年和2025年获得. Proof-of-concept studies for crofelemer in SBS and microvillus inclusion disease are underway in the US, EU, and Middle East/North Africa regions, with results expected by 2024 and 2025.